Work with thought leaders and academic experts in cancer research
Companies can greatly benefit from working with experts in the field of Cancer Research. These researchers bring a deep understanding of the disease and its mechanisms, allowing them to contribute valuable insights and expertise. Here are some ways companies can collaborate with academic researchers in Cancer Research: 1. Drug Discovery and Development: Academic researchers can assist in the discovery and development of new cancer drugs, providing expertise in target identification, preclinical testing, and clinical trials. 2. Biomarker Identification: Researchers can help identify biomarkers that can be used for early cancer detection, patient stratification, and monitoring treatment response. 3. Genomic Analysis: Experts in Cancer Research can analyze genomic data to identify genetic mutations and variations associated with cancer, enabling personalized treatment approaches. 4. Translational Research: Collaboration with academic researchers can facilitate the translation of basic research findings into clinical applications, bridging the gap between bench and bedside. 5. Clinical Trials: Companies can partner with academic researchers to conduct clinical trials, leveraging their expertise in trial design, patient recruitment, and data analysis. 6. Data Analytics: Researchers can apply advanced data analytics techniques to large-scale cancer datasets, uncovering patterns and insights that can inform treatment strategies. 7. Collaborative Research Projects: Joint research projects between companies and academic researchers can lead to innovative solutions and breakthrough discoveries in cancer treatment and prevention. 8. Education and Training: Academic researchers can provide educational programs and training to company employees, keeping them updated on the latest advancements in Cancer Research. 9. Intellectual Property: Collaboration with academic researchers can result in the generation of intellectual property, including patents and publications, which can enhance a company's competitive advantage. 10. Access to Networks and Resources: Academic researchers have access to extensive networks and resources, including collaborations with other experts, funding opportunities, and state-of-the-art facilities.
Experts on NotedSource with backgrounds in cancer research include Ramy Ayoub, Michael W Harman, Boris Leibovitch, Jeffrey Townsend, Edoardo Airoldi, Lee Weinstein, Jennifer Aaker, Liam D. Hendrikse, Ph.D., Giuliana Noratto, Marina Baretti, Ramy Ayoub, Timothy Sears, Katelyn Katelyn Masiuk, Jens Hegg, Kayvan Najarian, Amir Manbachi, Dona SLEIMAN, Olivier Saulnier, AMAN SHARMA, Ernesto Lowy, Niko Popitsch, and PRABIN KUMAR MAJHI.
Ramy Ayoub
PhD Candidate Medical Biophysics
Most Relevant Research Interests
Other Research Interests (17)
About
Most Relevant Publications (2+)
7 total publications
QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY
Neuro-Oncology / Jun 01, 2018
Ayoub, R., Miller, F., Beera, K., de Medeiros, C., Laughlin, S., Bouffet, E., & Mabbott, D. (2018). QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY. Neuro-Oncology, 20(suppl_2), i168–i168. https://doi.org/10.1093/neuonc/noy059.634
MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma
Neuro-Oncology / Jun 01, 2022
Smith, K., Bihannic, L., Gudenas, B., Gao, Q., Haldipur, P., Tao, R., Iskusnykh, I., Chizhikov, V., Scoggins, M., Zhang, S., Edwards, A., Deng, M., Glass, I., Overman, L., Millman, J., Sjoboen, A., Hadley, J., Mankad, K., Onar-Thomas, A., … Northcott, P. (2022). MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma. Neuro-Oncology, 24(Supplement_1), i124–i125. https://doi.org/10.1093/neuonc/noac079.452
Michael W Harman
Distinguished Subject Matter Expert & Leader in Medical Technologies.
Most Relevant Research Interests
Other Research Interests (16)
About
Most Relevant Publications (3+)
15 total publications
The induction of endoreduplication and polyploidy by elevated expression of 14-3-3γ
Genes & Cancer / Dec 24, 2017
Gomes, C. J., Centuori, S. M., Harman, M. W., Putnam, C. W., Wolgemuth, C. W., & Martinez, J. D. (2017). The induction of endoreduplication and polyploidy by elevated expression of 14-3-3γ. Genes & Cancer, 8(11–12), 771–783. https://doi.org/10.18632/genesandcancer.161
Abstract 3591: Expression of 14-3-3 gamma stabilizes polyploidization in NSCLC cells
Cancer Research / Jul 15, 2016
Gomes, C. J., Harman, M., Centuori, S., Wolgemuth, C., & Martinez, J. (2016). Abstract 3591: Expression of 14-3-3 gamma stabilizes polyploidization in NSCLC cells. Cancer Research, 76(14_Supplement), 3591–3591. https://doi.org/10.1158/1538-7445.am2016-3591
Abstract 2066: Aberrant upregulation of 14-3-3 gamma promotes mononucleated polyploidization in human lung cancers
Cancer Research / Aug 01, 2015
Gomes, C. J., Harman, M., Martinez, J., & Centuori, S. (2015). Abstract 2066: Aberrant upregulation of 14-3-3 gamma promotes mononucleated polyploidization in human lung cancers. Cancer Research, 75(15_Supplement), 2066–2066. https://doi.org/10.1158/1538-7445.am2015-2066
Boris Leibovitch
Experienced wet lab and in teaching Molecular Cell biologist, geneticist, cancer biologist in Academia
Most Relevant Research Interests
Other Research Interests (11)
About
Most Relevant Publications (2+)
22 total publications
Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
Molecular Cancer Therapeutics / Aug 01, 2015
Kwon, Y.-J., Petrie, K., Leibovitch, B. A., Zeng, L., Mezei, M., Howell, L., Gil, V., Christova, R., Bansal, N., Yang, S., Sharma, R., Ariztia, E. V., Frankum, J., Brough, R., Sbirkov, Y., Ashworth, A., Lord, C. J., Zelent, A., Farias, E., … Waxman, S. (2015). Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 14(8), 1824–1836. https://doi.org/10.1158/1535-7163.mct-14-0980-t
Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1
Translational Oncology / Feb 01, 2022
Kadamb, R., Leibovitch, B. A., Farias, E. F., Dahiya, N., Suryawanshi, H., Bansal, N., & Waxman, S. (2022). Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1. Translational Oncology, 16, 101320. https://doi.org/10.1016/j.tranon.2021.101320
Jeffrey Townsend
Professor of Biostatistics and Ecology & Evolutionary Biology
Most Relevant Research Interests
Other Research Interests (78)
About
Most Relevant Publications (18+)
207 total publications
Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR
Cancer Research / Dec 05, 2022
Mandell, J. D., Cannataro, V. L., & Townsend, J. P. (2022). Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR. Cancer Research, 83(4), 500–505. https://doi.org/10.1158/0008-5472.can-22-1508
Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia
Leukemia / Nov 11, 2022
Mandell, J. D., Fisk, J. N., Cyrenne, E., Xu, M. L., Cannataro, V. L., & Townsend, J. P. (2022). Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia. Leukemia, 36(12), 2931–2933. https://doi.org/10.1038/s41375-022-01752-5
Cancer Relevance of Human Genes
JNCI: Journal of the National Cancer Institute / Apr 13, 2022
Qing, T., Mohsen, H., Cannataro, V. L., Marczyk, M., Rozenblit, M., Foldi, J., Murray, M., Townsend, J. P., Kluger, Y., Gerstein, M., & Pusztai, L. (2022). Cancer Relevance of Human Genes. JNCI: Journal of the National Cancer Institute, 114(7), 988–995. https://doi.org/10.1093/jnci/djac068
Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma
Cancer Letters / Feb 01, 2022
Fisk, J. N., Mahal, A. R., Dornburg, A., Gaffney, S. G., Aneja, S., Contessa, J. N., Rimm, D., Yu, J. B., & Townsend, J. P. (2022). Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma. Cancer Letters, 526, 346–351. https://doi.org/10.1016/j.canlet.2021.11.011
Environmental and sex-specific molecular signatures of glioma causation
Neuro-Oncology / May 04, 2021
Claus, E. B., Cannataro, V. L., Gaffney, S. G., & Townsend, J. P. (2021). Environmental and sex-specific molecular signatures of glioma causation. Neuro-Oncology, 24(1), 29–36. https://doi.org/10.1093/neuonc/noab103
Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors—on average—to exhibit a lower mutation burden
Lung Cancer / Apr 01, 2022
Tan, C., Mandell, J. D., Dasari, K., Cannataro, V. L., Alfaro-Murillo, J. A., & Townsend, J. P. (2022). Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors—on average—to exhibit a lower mutation burden. Lung Cancer, 166, 265–269. https://doi.org/10.1016/j.lungcan.2021.10.008
Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma
Oral Oncology / Feb 01, 2020
Lu, L., Gaffney, S. G., Cannataro, V. L., & Townsend, J. (2020). Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma. Oral Oncology, 101, 104554. https://doi.org/10.1016/j.oraloncology.2019.104554
Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck
Clinical Cancer Research / Jun 01, 2019
Lee, J. W., Parameswaran, J., Sandoval-Schaefer, T., Eoh, K. J., Yang, D., Zhu, F., Mehra, R., Sharma, R., Gaffney, S. G., Perry, E. B., Townsend, J. P., Serebriiskii, I. G., Golemis, E. A., Issaeva, N., Yarbrough, W. G., Koo, J. S., & Burtness, B. (2019). Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 25(11), 3430–3442. https://doi.org/10.1158/1078-0432.ccr-18-0440
APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma
Oncogene / Jan 15, 2019
Cannataro, V. L., Gaffney, S. G., Sasaki, T., Issaeva, N., Grewal, N. K. S., Grandis, J. R., Yarbrough, W. G., Burtness, B., Anderson, K. S., & Townsend, J. P. (2019). APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma. Oncogene, 38(18), 3475–3487. https://doi.org/10.1038/s41388-018-0657-6
Wagging the long tail of drivers of prostate cancer
PLOS Genetics / Jan 17, 2019
Cannataro, V. L., & Townsend, J. P. (2019). Wagging the long tail of drivers of prostate cancer. PLOS Genetics, 15(1), e1007820. https://doi.org/10.1371/journal.pgen.1007820
Somatic evolutionary timings of driver mutations
BMC Cancer / Jan 18, 2018
Gomez, K., Miura, S., Huuki, L. A., Spell, B. S., Townsend, J. P., & Kumar, S. (2018). Somatic evolutionary timings of driver mutations. BMC Cancer, 18(1). https://doi.org/10.1186/s12885-017-3977-y
Effect Sizes of Somatic Mutations in Cancer
JNCI: Journal of the National Cancer Institute / Oct 26, 2018
Cannataro, V. L., Gaffney, S. G., & Townsend, J. P. (2018). Effect Sizes of Somatic Mutations in Cancer. JNCI: Journal of the National Cancer Institute, 110(11), 1171–1177. https://doi.org/10.1093/jnci/djy168
Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C
Oncogene / Feb 16, 2018
Cannataro, V. L., Gaffney, S. G., Stender, C., Zhao, Z.-M., Philips, M., Greenstein, A. E., & Townsend, J. P. (2018). Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C. Oncogene, 37(18), 2444–2455. https://doi.org/10.1038/s41388-017-0105-z
CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma
Frontiers in Oncology / Apr 04, 2018
Chen, W. S., Bindra, R. S., Mo, A., Hayman, T., Husain, Z., Contessa, J. N., Gaffney, S. G., Townsend, J. P., & Yu, J. B. (2018). CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 8. https://doi.org/10.3389/fonc.2018.00095
The ancestral levels of transcription and the evolution of sexual phenotypes in filamentous fungi
PLOS Genetics / Jul 13, 2017
Trail, F., Wang, Z., Stefanko, K., Cubba, C., & Townsend, J. P. (2017). The ancestral levels of transcription and the evolution of sexual phenotypes in filamentous fungi. PLOS Genetics, 13(7), e1006867. https://doi.org/10.1371/journal.pgen.1006867
PhyloOncology: Understanding cancer through phylogenetic analysis
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer / Apr 01, 2017
Somarelli, J. A., Ware, K. E., Kostadinov, R., Robinson, J. M., Amri, H., Abu-Asab, M., Fourie, N., Diogo, R., Swofford, D., & Townsend, J. P. (2017). PhyloOncology: Understanding cancer through phylogenetic analysis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1867(2), 101–108. https://doi.org/10.1016/j.bbcan.2016.10.006
Inferring the Origin of Metastases from Cancer Phylogenies
Cancer Research / Sep 30, 2015
Hong, W. S., Shpak, M., & Townsend, J. P. (2015). Inferring the Origin of Metastases from Cancer Phylogenies. Cancer Research, 75(19), 4021–4025. https://doi.org/10.1158/0008-5472.can-15-1889
Radiation-Specific Clinical Data Should Be Included in Existing Large-Scale Genomic Datasets
International Journal of Radiation Oncology*Biology*Physics / May 01, 2017
Chen, W. S., Townsend, J. P., & Yu, J. B. (2017). Radiation-Specific Clinical Data Should Be Included in Existing Large-Scale Genomic Datasets. International Journal of Radiation Oncology*Biology*Physics, 98(1), 8–10. https://doi.org/10.1016/j.ijrobp.2017.01.023
Edoardo Airoldi
Professor of Statistics & Data Science Temple University & PI, Harvard University
Most Relevant Research Interests
Other Research Interests (63)
About
Most Relevant Publications (1+)
106 total publications
Accounting for Experimental Noise Reveals That mRNA Levels, Amplified by Post-Transcriptional Processes, Largely Determine Steady-State Protein Levels in Yeast
PLOS Genetics / May 07, 2015
Csárdi, G., Franks, A., Choi, D. S., Airoldi, E. M., & Drummond, D. A. (2015). Accounting for Experimental Noise Reveals That mRNA Levels, Amplified by Post-Transcriptional Processes, Largely Determine Steady-State Protein Levels in Yeast. PLOS Genetics, 11(5), e1005206. https://doi.org/10.1371/journal.pgen.1005206
Lee Weinstein
STEM Educator
Most Relevant Research Interests
Other Research Interests (34)
About
Most Relevant Publications (1+)
22 total publications
Coupling endoplasmic reticulum stress to the cell death program in mouse melanoma cells: effect of curcumin
Apoptosis / May 21, 2008
Bakhshi, J., Weinstein, L., Poksay, K. S., Nishinaga, B., Bredesen, D. E., & Rao, R. V. (2008). Coupling endoplasmic reticulum stress to the cell death program in mouse melanoma cells: effect of curcumin. Apoptosis, 13(7), 904–914. https://doi.org/10.1007/s10495-008-0221-x
Jennifer Aaker
General Atlantic Professor, Stanford University
Most Relevant Research Interests
Other Research Interests (38)
About
Most Relevant Publications (1+)
79 total publications
SPECIAL SYMPOSIUM LECTURE: SIR HANS L. KORNBERG
Advances in Enzyme Regulation / Jan 01, 2002
SPECIAL SYMPOSIUM LECTURE: SIR HANS L. KORNBERG. (2002). Advances in Enzyme Regulation, 42, EX17. https://doi.org/10.1016/s0065-2571(01)00055-3
Liam D. Hendrikse, Ph.D.
Bioinformatician at the University Health Network in Toronto, CA, specializing in computational cancer research using various sequencing modalities.
Most Relevant Research Interests
Other Research Interests (13)
About
Most Relevant Publications (3+)
10 total publications
MDB-07. MYC AND TGFΒ PROMOTE GROUP 3 MEDULLOBLASTOMA TUMOR RESISTANCE THROUGH DEREGULATION OF KDM2B TARGETS
Neuro-Oncology / Jun 01, 2023
Qadeer, Z., Westelman, S., Johnson, M., Grele, S., Hou, E., Hendrikse, L., Wang, L., Husain, S., Beytagh, M. C., Schmidt, C., Huang, M., Taylor, M., & Weiss, W. (2023). MDB-07. MYC AND TGFΒ PROMOTE GROUP 3 MEDULLOBLASTOMA TUMOR RESISTANCE THROUGH DEREGULATION OF KDM2B TARGETS. Neuro-Oncology, 25(Supplement_1), i62–i63. https://doi.org/10.1093/neuonc/noad073.240
MDB-21. THE OTX2-REGULATED ALTERNATIVE SPLICING LANDSCAPE CONTROLS DIFFERENTIATION AND RECONSTITUTES THE DEVELOPMENTAL ORIGINS OF GROUP 3 MEDULLOBLASTOMA
Neuro-Oncology / Jun 01, 2023
Saulnier, O., Zagozewski, J., Liang, L., Hendrikse, L. D., Gordon, V., Aldinger, K. A., Haldipur, P., Borlase, S., Coudiere-Morrison, L., Layug, P., Cai, T., Porter, C. J., Richard, S., Doble, B. W., Millen, K. J., Taylor, M. D., & Werbowetski-Ogilvie, T. E. (2023). MDB-21. THE OTX2-REGULATED ALTERNATIVE SPLICING LANDSCAPE CONTROLS DIFFERENTIATION AND RECONSTITUTES THE DEVELOPMENTAL ORIGINS OF GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 25(Supplement_1), i66–i67. https://doi.org/10.1093/neuonc/noad073.254
DDDR-33. TARGETING TGFΒ PATHWAY DEPENDENCIES IN GROUP 3 MEDULLOBLASTOMA
Neuro-Oncology / Nov 01, 2022
Qadeer, Z., Westelman, S., Johnson, M., Grele, S., Hendrikse, L., Taylor, M., & Weiss, W. (2022). DDDR-33. TARGETING TGFΒ PATHWAY DEPENDENCIES IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 24(Supplement_7), vii106–vii106. https://doi.org/10.1093/neuonc/noac209.398
Giuliana Noratto
Food Scientist PhD and Registered Dietician - Texas A&M University
Most Relevant Research Interests
Other Research Interests (49)
About
Most Relevant Publications (4+)
91 total publications
Calotropis Procera Induced Caspase-Dependent Apoptosis and Impaired Akt/mTOR Signaling in 4T1 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry / Nov 01, 2022
Rabelo, A. C. S., Miglino, M. A., Arbizu, S., Carreira, A. C. O., Filho, A. J. C., Carneiro, F. J. C., Layosa, M. A. A., & Noratto, G. (2022). Calotropis Procera Induced Caspase-Dependent Apoptosis and Impaired Akt/mTOR Signaling in 4T1 Breast Cancer Cells. Anti-Cancer Agents in Medicinal Chemistry, 22(18), 3136–3147. https://doi.org/10.2174/1871520622666220608122154
Dark Sweet Cherry (Prunus avium) Phenolics Enriched in Anthocyanins Induced Apoptosis in MDA-MB-453 Breast Cancer Cells through MAPK-Dependent Signaling and Reduced Invasion via Akt and PLCγ-1 Downregulation
Nutrition and Cancer / Sep 14, 2020
Layosa, M. A. A., Lage, N. N., Chew, B. P., Atienza, L., Mertens-Talcott, S., Talcott, S., & Noratto, G. D. (2020). Dark Sweet Cherry (Prunus avium) Phenolics Enriched in Anthocyanins Induced Apoptosis in MDA-MB-453 Breast Cancer Cells through MAPK-Dependent Signaling and Reduced Invasion via Akt and PLCγ-1 Downregulation. Nutrition and Cancer, 73(10), 1985–1997. https://doi.org/10.1080/01635581.2020.1817514
Pro-Apoptotic Activities of Polyphenolics From Açai (Euterpe oleraceaMartius) in Human SW-480 Colon Cancer Cells
Nutrition and Cancer / Oct 20, 2014
Dias, M. M. dos S., Noratto, G., Martino, H. S. D., Arbizu, S., Peluzio, M. do C. G., Talcott, S., Ramos, A. M., & Mertens-Talcott, S. U. (2014). Pro-Apoptotic Activities of Polyphenolics From Açai (Euterpe oleraceaMartius) in Human SW-480 Colon Cancer Cells. Nutrition and Cancer, 66(8), 1394–1405. https://doi.org/10.1080/01635581.2014.956252
Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: Role of Sp transcription factors and microRNA-27a:ZBTB10
Molecular Carcinogenesis / Mar 07, 2012
Mertens-Talcott, S. U., Noratto, G. D., Li, X., Angel-Morales, G., Bertoldi, M. C., & Safe, S. (2012). Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: Role of Sp transcription factors and microRNA-27a:ZBTB10. Molecular Carcinogenesis, 52(8), 591–602. Portico. https://doi.org/10.1002/mc.21893
Marina Baretti
I am a clinical translational researcher in gastrointestinal (GI) oncology, collaborating closely with laboratory-based researchers to move laboratory findings into patients and to answer important clinical questions.
Most Relevant Research Interests
Other Research Interests (17)
About
Most Relevant Publications (14+)
57 total publications
The role of epigenetic therapies in colorectal cancer
Current Problems in Cancer / Nov 01, 2018
Baretti, M., & Azad, N. S. (2018). The role of epigenetic therapies in colorectal cancer. Current Problems in Cancer, 42(6), 530–547. https://doi.org/10.1016/j.currproblcancer.2018.03.001
KRAS
mutation in lung metastases from
colorectal cancer: prognostic
implications
Cancer Medicine / Dec 29, 2015
Ghidini, M., Personeni, N., Bozzarelli, S., Baretti, M., Basso, G., Bianchi, P., Tronconi, M. C., Pressiani, T., Grizzi, F., Giordano, L., Malesci, A., Alloisio, M., Laghi, L., Santoro, A., & Rimassa, L. (2015). <scp>KRAS</scp> mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Medicine, 5(2), 256–264. Portico. https://doi.org/10.1002/cam4.592
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures
JCO Precision Oncology / Jun 01, 2022
Mody, K., Jain, P., El-Refai, S. M., Azad, N. S., Zabransky, D. J., Baretti, M., Shroff, R. T., Kelley, R. K., El-Khouiery, A. B., Hockenberry, A. J., Lau, D., Lesinski, G. B., & Yarchoan, M. (2022). Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. JCO Precision Oncology, 6. https://doi.org/10.1200/po.21.00510
Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma.
Journal of Clinical Oncology / May 20, 2018
Baretti, M., Durham, J. N., Walker, R., Mitcheltree, A.-L., Christmas, B., Cope, L., Jaffee, E. M., & Azad, N. S. (2018). Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma. Journal of Clinical Oncology, 36(15_suppl), TPS4151–TPS4151. https://doi.org/10.1200/jco.2018.36.15_suppl.tps4151
Expanding the immunotherapy roadmap for hepatocellular carcinoma
Cancer Cell / Mar 01, 2022
Baretti, M., Kim, A. K., & Anders, R. A. (2022). Expanding the immunotherapy roadmap for hepatocellular carcinoma. Cancer Cell, 40(3), 252–254. https://doi.org/10.1016/j.ccell.2022.02.017
Precision Cancer Trials With Immunomodulatory Agents
The Cancer Journal / Jul 01, 2019
Baretti, M., & Azad, N. S. (2019). Precision Cancer Trials With Immunomodulatory Agents. The Cancer Journal, 25(4), 287–295. https://doi.org/10.1097/ppo.0000000000000390
Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors
Cancers / Oct 30, 2022
Chen, K. Y., Popovic, A., Hsiehchen, D., Baretti, M., Griffith, P., Bista, R., Baghdadi, A., Kamel, I. R., Simon, S. M., Migler, R. D., & Yarchoan, M. (2022). Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers, 14(21), 5347. https://doi.org/10.3390/cancers14215347
Abstract 3679: DNAJB1-PRKACA fusion in fibrolamellar hepatocellular carcinoma induces glutamine addiction and an immunosuppressive tumor microenvironment
Cancer Research / Apr 04, 2023
Kamdar, Z., Lopez-Vidal, T., Howe, K., Munjal, K., Saeed, A., Zabransky, D., Shu, D., Longway, G., Kartalia, E., Leatherman, J., Mohan, A., Khare, P., Zhang, C., Le, A., Pearce, E., Furth, M., Baretti, M., Leone, R., Jaffee, E., & Yarchoan, M. (2023). Abstract 3679: DNAJB1-PRKACA fusion in fibrolamellar hepatocellular carcinoma induces glutamine addiction and an immunosuppressive tumor microenvironment. Cancer Research, 83(7_Supplement), 3679–3679. https://doi.org/10.1158/1538-7445.am2023-3679
Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes in rectal cancer.
Journal of Clinical Oncology / Feb 01, 2019
Baretti, M., Fu, W., Wang, H., Anders, R. A., Azad, N. S., & Zhu, Q. (2019). Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes in rectal cancer. Journal of Clinical Oncology, 37(4_suppl), 570–570. https://doi.org/10.1200/jco.2019.37.4_suppl.570
The impact of the immune microenvironment in patients with GEP-NETs.
Journal of Clinical Oncology / Feb 01, 2019
Baretti, M., Zhu, Q., Zahurak, M., Pawlik, T. M., Anders, R. A., & De Jesus-Acosta, A. (2019). The impact of the immune microenvironment in patients with GEP-NETs. Journal of Clinical Oncology, 37(4_suppl), 267–267. https://doi.org/10.1200/jco.2019.37.4_suppl.267
Evaluation of prognostic factors and of the role of adjuvant chemotherapy in patients with invasive carcinoma derived from intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.
Journal of Clinical Oncology / May 20, 2010
Vasile, E., Caponi, S., Lucchesi, M., Del Chiaro, M., Funel, N., Ginocchi, L., Campani, D., Falcone, A., Boggi, U., & Mosca, F. (2010). Evaluation of prognostic factors and of the role of adjuvant chemotherapy in patients with invasive carcinoma derived from intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. Journal of Clinical Oncology, 28(15_suppl), e14605–e14605. https://doi.org/10.1200/jco.2010.28.15_suppl.e14605
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?
Cancer Biology & Therapy / Apr 13, 2018
Baretti, M., Personeni, N., Destro, A., Santoro, A., & Rimassa, L. (2018). Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity? Cancer Biology & Therapy, 19(8), 659–663. https://doi.org/10.1080/15384047.2018.1450117
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications
Gastric Cancer / Aug 16, 2016
Personeni, N., Baretti, M., Bozzarelli, S., Spaggiari, P., Rubino, L., Tronconi, M. C., Fumagalli Romario, U., Rosati, R., Giordano, L., Roncalli, M., Santoro, A., & Rimassa, L. (2016). Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Gastric Cancer, 20(3), 428–437. https://doi.org/10.1007/s10120-016-0625-1
Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice
Lung Cancer / May 01, 2016
Metro, G., Ricciuti, B., Chiari, R., Baretti, M., Falcinelli, L., Giannarelli, D., Sidoni, A., Mountzios, G., Crinò, L., Bellezza, G., Rebonato, A., Ferolla, P., & Toschi, L. (2016). Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer, 95, 82–87. https://doi.org/10.1016/j.lungcan.2016.03.006
Ramy Ayoub
Ph.D. Candidate, University of Toronto | SickKids Hospital
Most Relevant Research Interests
Other Research Interests (15)
About
Most Relevant Publications (1+)
7 total publications
QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY
Neuro-Oncology / Jun 01, 2018
Ayoub, R., Miller, F., Beera, K., de Medeiros, C., Laughlin, S., Bouffet, E., & Mabbott, D. (2018). QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY. Neuro-Oncology, 20(suppl_2), i168–i168. https://doi.org/10.1093/neuonc/noy059.634
Timothy Sears
PhD student, Bioinformatics, UC San Diego
Most Relevant Research Interests
Other Research Interests (14)
About
Most Relevant Publications (3+)
7 total publications
Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
Clinical Cancer Research / May 02, 2023
Bui, N. Q., Nemat-Gorgani, N., Subramanian, A., Torres, I. A., Lohman, M., Sears, T. J., van de Rijn, M., Charville, G. W., Becker, H.-C., Wang, D. S., Hwang, G. L., Ganjoo, K. N., & Moding, E. J. (2023). Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis. Clinical Cancer Research, 29(14), 2612–2620. https://doi.org/10.1158/1078-0432.ccr-23-0250
Abstract 5960: Identification and validation of sarcoma cellular ecosystems associated with prognosis and predictive of immunotherapy response
Cancer Research / Apr 04, 2023
Subramanian, A., Nemat-Gorgani, N., Ellis-Caleo, T. J., van IJzendoorn, D. G. P., Sears, T. J., Somani, A., Luca, B. A., Zhou, M. Y., Bradic, M., Torres, I. A., Oladipo, E., New, C., Kenney, D. E., Avedian, R. S., Steffner, R. J., Binkley, M. S., Mohler, D. G., Tap, W. D., D’Angelo, S. P., … Moding, E. J. (2023). Abstract 5960: Identification and validation of sarcoma cellular ecosystems associated with prognosis and predictive of immunotherapy response. Cancer Research, 83(7_Supplement), 5960–5960. https://doi.org/10.1158/1538-7445.am2023-5960
Abstract 3825: Germline modifiers of the tumor immune microenvironment reveal drivers of immunotherapy response
Cancer Research / Jun 15, 2022
Pagadala, M., Wu, V., Pérez-Guijarro, E., Kim, H., Castro, A., Talwar, J., Gonzalez-Colin, C., Cao, S., Schmiedel, B. J., Sears, T., Goudarzi, S., Kirani, D., Salem, R. M., Morris, G. P., Harismendy, O., Patel, S. P., Mesirov, J. P., Zanetti, M., Day, C.-P., … Carter, H. (2022). Abstract 3825: Germline modifiers of the tumor immune microenvironment reveal drivers of immunotherapy response. Cancer Research, 82(12_Supplement), 3825–3825. https://doi.org/10.1158/1538-7445.am2022-3825
Katelyn Katelyn Masiuk
Co-Founder and CSO at Immunovec
Most Relevant Research Interests
Other Research Interests (25)
About
Most Relevant Publications (2+)
13 total publications
Pharmacologic Inhibition of ALK5 Causes Selective Induction of Terminal Differentiation in Mouse Keratinocytes Expressing Oncogenic HRAS
Molecular Cancer Research / Jun 01, 2011
Markell, L. M., Masiuk, K. E., Blazanin, N., & Glick, A. B. (2011). Pharmacologic Inhibition of ALK5 Causes Selective Induction of Terminal Differentiation in Mouse Keratinocytes Expressing Oncogenic HRAS. Molecular Cancer Research, 9(6), 746–756. https://doi.org/10.1158/1541-7786.mcr-11-0112
Use of a TGFβ type I receptor inhibitor in mouse skin carcinogenesis reveals a dual role for TGFβ signaling in tumor promotion and progression
Carcinogenesis / Sep 17, 2010
Mordasky Markell, L., Pérez-Lorenzo, R., Masiuk, K. E., Kennett, M. J., & Glick, A. B. (2010). Use of a TGFβ type I receptor inhibitor in mouse skin carcinogenesis reveals a dual role for TGFβ signaling in tumor promotion and progression. Carcinogenesis, 31(12), 2127–2135. https://doi.org/10.1093/carcin/bgq191
Jens Hegg
Professor studying chemicalAnd isotopic records in animal hard parts.
Most Relevant Research Interests
Other Research Interests (18)
Most Relevant Publications (1+)
20 total publications
Ratcheting Myc
Cancer Cell / Dec 01, 2008
Freie, B. W., & Eisenman, R. N. (2008). Ratcheting Myc. Cancer Cell, 14(6), 425–426. https://doi.org/10.1016/j.ccr.2008.11.008
Kayvan Najarian
Professor of Comp Med and Bioinf, Emergency Med, and Electrical and Comp Engineering
Most Relevant Research Interests
Other Research Interests (40)
Most Relevant Publications (1+)
108 total publications
Signatures of tumor–immune interactions as biomarkers for breast cancer prognosis
Future Oncology / Jun 01, 2012
Manjili, M. H., Najarian, K., & Wang, X.-Y. (2012). Signatures of tumor–immune interactions as biomarkers for breast cancer prognosis. Future Oncology, 8(6), 703–711. https://doi.org/10.2217/fon.12.57
Amir Manbachi
Co-director and Founder of the Johns Hopkins HEPIUS Innovation Lab
Most Relevant Research Interests
Other Research Interests (56)
Most Relevant Publications (3+)
92 total publications
Reusable Core Needle Biopsy Device for Low-Resource Settings
Journal of Global Oncology / Oct 01, 2018
Callanan, M., Zawicki, V., Hinson, L., Lee, M., Triantis, S., Manbachi, A., & Harvey, S. (2018). Reusable Core Needle Biopsy Device for Low-Resource Settings. Journal of Global Oncology, 4(Supplement 3), 47s–47s. https://doi.org/10.1200/jgo.18.10550
Towards standardization of the parameters for opening the blood–brain barrier with focused ultrasound to treat glioblastoma multiforme: A systematic review of the devices, animal models, and therapeutic compounds used in rodent tumor models
Frontiers in Oncology / Feb 16, 2023
Thombre, R., Mess, G., Kempski Leadingham, K. M., Kapoor, S., Hersh, A., Acord, M., Kaovasia, T., Theodore, N., Tyler, B., & Manbachi, A. (2023). Towards standardization of the parameters for opening the blood–brain barrier with focused ultrasound to treat glioblastoma multiforme: A systematic review of the devices, animal models, and therapeutic compounds used in rodent tumor models. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1072780
Applications of Focused Ultrasound for the Treatment of Glioblastoma: A New Frontier
Cancers / Oct 08, 2022
Hersh, A. M., Bhimreddy, M., Weber-Levine, C., Jiang, K., Alomari, S., Theodore, N., Manbachi, A., & Tyler, B. M. (2022). Applications of Focused Ultrasound for the Treatment of Glioblastoma: A New Frontier. Cancers, 14(19), 4920. https://doi.org/10.3390/cancers14194920
Dona SLEIMAN
After completing my BS in Biochemistry in Beirut, I pursued a master’s degree in Genetics followed by a Master 2 degree in Molecular Engineering. I received my PhD in Biochemistry and Biophysics in 2013 at Paris Descartes University with the highest honors & Committee Praise. Throughout my thesis and post-doctoral experience, I have studied different aspects of protein/nucleic acid interactions using several biophysical techniques.
Most Relevant Research Interests
Other Research Interests (8)
Most Relevant Publications (2+)
4 total publications
Initiation of HIV-1 reverse transcription and functional role of nucleocapsid-mediated tRNA/viral genome interactions
Virus Research / Nov 01, 2012
Sleiman, D., Goldschmidt, V., Barraud, P., Marquet, R., Paillart, J.-C., & Tisné, C. (2012). Initiation of HIV-1 reverse transcription and functional role of nucleocapsid-mediated tRNA/viral genome interactions. Virus Research, 169(2), 324–339. https://doi.org/10.1016/j.virusres.2012.06.006
Cyclic di-AMP regulation of osmotic homeostasis is essential in Group B Streptococcus
PLOS Genetics / Apr 16, 2018
Devaux, L., Sleiman, D., Mazzuoli, M.-V., Gominet, M., Lanotte, P., Trieu-Cuot, P., Kaminski, P.-A., & Firon, A. (2018). Cyclic di-AMP regulation of osmotic homeostasis is essential in Group B Streptococcus. PLOS Genetics, 14(4), e1007342. https://doi.org/10.1371/journal.pgen.1007342
Olivier Saulnier
The Hospital for Sick Children
Most Relevant Research Interests
Other Research Interests (17)
Most Relevant Publications (5+)
25 total publications
EPEN-52. METABOLIC REGULATION OF THE EPIGENOME DRIVES LETHAL INFANTILE EPENDYMOMA
Neuro-Oncology / Dec 01, 2020
Kumar, S., Michealraj, A., Kim, L., Rich, J., & Taylor, M. (2020). EPEN-52. METABOLIC REGULATION OF THE EPIGENOME DRIVES LETHAL INFANTILE EPENDYMOMA. Neuro-Oncology, 22(Supplement_3), iii318–iii318. https://doi.org/10.1093/neuonc/noaa222.185
MDB-21. THE OTX2-REGULATED ALTERNATIVE SPLICING LANDSCAPE CONTROLS DIFFERENTIATION AND RECONSTITUTES THE DEVELOPMENTAL ORIGINS OF GROUP 3 MEDULLOBLASTOMA
Neuro-Oncology / Jun 01, 2023
Saulnier, O., Zagozewski, J., Liang, L., Hendrikse, L. D., Gordon, V., Aldinger, K. A., Haldipur, P., Borlase, S., Coudiere-Morrison, L., Layug, P., Cai, T., Porter, C. J., Richard, S., Doble, B. W., Millen, K. J., Taylor, M. D., & Werbowetski-Ogilvie, T. E. (2023). MDB-21. THE OTX2-REGULATED ALTERNATIVE SPLICING LANDSCAPE CONTROLS DIFFERENTIATION AND RECONSTITUTES THE DEVELOPMENTAL ORIGINS OF GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 25(Supplement_1), i66–i67. https://doi.org/10.1093/neuonc/noad073.254
BIOL-23. LOSS OF MICRORNAS COOPERATES WITH TUMOR SUPPRESSORS TO INITIATE MYC-DEPENDENT METASTATIC MEDULLOBLASTOMA
Neuro-Oncology / Jun 01, 2023
Llaguno, S. A., Nazarenko, I., Chen, Y., Sun, D., Gudenas, B., Saulnier, O., Rocca, G. L., Pedraza, A., Burns, D., Bale, T., Ventura, A., Northcott, P., Taylor, M., & Parada, L. (2023). BIOL-23. LOSS OF MICRORNAS COOPERATES WITH TUMOR SUPPRESSORS TO INITIATE MYC-DEPENDENT METASTATIC MEDULLOBLASTOMA. Neuro-Oncology, 25(Supplement_1), i11–i11. https://doi.org/10.1093/neuonc/noad073.042
Abstract IA009: Oncogenic transcription factors drive highly tumor-specific LincRNA
Clinical Cancer Research / Sep 15, 2022
Delattre, O., Vibert, J., Saulnier, O., & Waterfall, J. (2022). Abstract IA009: Oncogenic transcription factors drive highly tumor-specific LincRNA. Clinical Cancer Research, 28(18_Supplement), IA009–IA009. https://doi.org/10.1158/1557-3265.sarcomas22-ia009
The LIN28B –let‐7–PBK
pathway is essential for group 3
medulloblastoma tumor growth and
survival
Molecular Oncology / Aug 07, 2023
Shahab, S. W., Roggeveen, C. M., Sun, J., Kunhiraman, H., McSwain, L. F., Juraschka, K., Kumar, S. A., Saulnier, O., Taylor, M. D., Schniederjan, M., Schnepp, R. W., MacDonald, T. J., & Kenney, A. M. (2023). The <scp>LIN28B</scp>–let‐7–<scp>PBK</scp> pathway is essential for group 3 medulloblastoma tumor growth and survival. Molecular Oncology. Portico. https://doi.org/10.1002/1878-0261.13477
AMAN SHARMA
Postdoctoral Research Fellow, Memorial Sloan Kettering Cancer Center.
Most Relevant Research Interests
Other Research Interests (11)
Most Relevant Publications (3+)
8 total publications
Inter-Individual Variation in Response to Estrogen in Human Breast Explants
Journal of Mammary Gland Biology and Neoplasia / Mar 01, 2020
Dunphy, K. A., Black, A. L., Roberts, A. L., Sharma, A., Li, Z., Suresh, S., Browne, E. P., Arcaro, K. F., Ser-Dolansky, J., Bigelow, C., Troester, M. A., Schneider, S. S., Makari-Judson, G., Crisi, G. M., & Jerry, D. J. (2020). Inter-Individual Variation in Response to Estrogen in Human Breast Explants. Journal of Mammary Gland Biology and Neoplasia, 25(1), 51–68. https://doi.org/10.1007/s10911-020-09446-3
Abstract P1-07-10: Estrogen-stimulated DNA damage in mammary epithelium varies among strains of rodents and women
Cancer Research / Feb 15, 2022
Dunphy, K. A., Sharma, A., Majhi, P., Schneider, S. S., Crisi, G. M., Makari-Judson, G., & Jerry, D. J. (2022). Abstract P1-07-10: Estrogen-stimulated DNA damage in mammary epithelium varies among strains of rodents and women. Cancer Research, 82(4_Supplement), P1-07-10-P1-07–10. https://doi.org/10.1158/1538-7445.sabcs21-p1-07-10
Abstract 3750: Xenoestrogens cause estrogen receptor-dependent R-loop formation and DNA damage
Cancer Research / Jul 01, 2018
Dunphy, K. A., Majhi, P. D., Sharma, A., Roberts, A. L., Daniele, E. A., Schneider, S. S., & Jerry, D. J. (2018). Abstract 3750: Xenoestrogens cause estrogen receptor-dependent R-loop formation and DNA damage. Cancer Research, 78(13_Supplement), 3750–3750. https://doi.org/10.1158/1538-7445.am2018-3750
Example cancer research projects
How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on cancer research?
Development of Targeted Therapies
An academic researcher in Cancer Research can collaborate with a pharmaceutical company to develop targeted therapies for specific types of cancer. By leveraging their expertise in molecular biology and drug discovery, the researcher can contribute to the design and optimization of novel drugs that selectively target cancer cells while minimizing side effects.
Identification of Novel Biomarkers
A company specializing in diagnostic tools can collaborate with a Cancer Research expert to identify novel biomarkers for early cancer detection. The researcher can utilize their knowledge of cancer biology and molecular techniques to identify specific biomarkers that can be incorporated into diagnostic tests, enabling early intervention and improved patient outcomes.
Genomic Analysis for Personalized Medicine
By partnering with an academic researcher in Cancer Research, a biotech company can leverage genomic analysis to develop personalized medicine approaches. The researcher can analyze genomic data from patients to identify genetic mutations and variations that can inform treatment decisions, leading to more targeted and effective therapies.
Development of Immunotherapies
Collaboration between a pharmaceutical company and a Cancer Research expert can lead to the development of innovative immunotherapies. The researcher can contribute their knowledge of the immune system and cancer immunology to design and optimize immunotherapeutic approaches, enhancing the company's portfolio of cancer treatments.
Exploration of Combination Therapies
An academic researcher in Cancer Research can collaborate with a company to explore combination therapies for cancer treatment. By combining different drugs or treatment modalities, the researcher can help identify synergistic effects and optimize treatment regimens, potentially improving patient outcomes and expanding the company's treatment options.